Current Clinical Practice: Low-Molecular-Weight Heparins in The Prophylaxis and Treatment of Thrombo-Embolic Disease

References

• Nicolaides, A. N. and Ramaswami, G. The Prevention of Venous Thromboembolism, Slide Lecture programme, Leo Pharmaceuticals.
   Google Scholar
• Barrowcliffe, T. W. (1995). Low-molecular-weight heparins. Br J Haematol, 90, 1–7.
   PubMed Web of Science ®Google Scholar
• Thromboembolic Risk Factors (THRIFT) Consensus Group, Risk of and prophylyaxis for venous throembolism in hospital patients of venous thromboembolism. BMJ 1992, 305, 567–574.
   Google Scholar
• Scurr, J. (1998). On behalf of the 2nd Thromboembolic Risk Factors (tHRiFT II) Consensus Group. Phlebology, 13, 87–97.
   Google Scholar
• Nurmohamed, M. T., Resendaal, F. R., Büller, H R., et al. (1992). LMWH versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet, 340, 152–6.
   PubMed Web of Science ®Google Scholar
• Leizorovicz, A., Haugh, M. C., Chapuis, F.-R. and Samana, M. M. (1992). Boissel J.-P. LMWH in the prevention of perioperative thrombosis. BMJ, 305, 913.
   PubMed Web of Science ®Google Scholar
• Palmer, A. J., Koppenagen, K., Kirchof, B., Weber, U. and Bergeman, R. (1997). Efficacy and safety of LMWF, UH and warfarin for thromboembolism prohpylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis, 27, 75–84.
   PubMedGoogle Scholar
• Planes, A., Vochelle, N., Darmon, J.-Y., Fagola, M., Beelaud, M. and Huet, Y. (1996). Risk of DVT after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet, 348, 224–8.
   PubMed Web of Science ®Google Scholar
• Bergqvist, D., Benoni, G., Björgell, O., et al. (1996). LMWH (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N. Eng J Med, 335, 696–700.
   PubMed Web of Science ®Google Scholar
• Dahl, O. E., Adreassen, G., Müuller;ller, C., et al. (1995). The effect of thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Throm Haemost, 73, 1094 (abstract 473).
   PubMed Web of Science ®Google Scholar
• Drugs and Therapeutics Bulletin, 36(4), April 1998.
   Google Scholar
• Kakkar, V. V., Cohen, A. T., Edmondson, R. A., et al. (1993). LMWH versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet, 341, 259–65.
   PubMed Web of Science ®Google Scholar
• Greer, I. A. and de Sweit, M. (1993). Thrombosis Prophylaxis in Obstetrics and Gyneacology. Brit Jour Obst and Gynae, 100, 37–40.
   PubMedGoogle Scholar
• Salzman, E. W. and Hirsch, J. (1982). Prevention of venous thromboembolism. In: Colman RW, Hirsch J, Marder V, Salzman EW, eds haemostasis and thrombosis: basic principles and clinical practice, New York: Lippincott, 986.
   Google Scholar
• Hirsch, J. and Levine, M. N. (1992). Low molecular weight heparin. Blood, 79, 1–17.
   PubMed Web of Science ®Google Scholar
• Hull, R. D., Raskob, G. G. F., et al. (1992). Subcutaneous low-molecular-weight hepain compared with intravenous heparin in the treatment of proximal vein thrombosis. N Eng J Med, 326, 975–82.
   PubMed Web of Science ®Google Scholar
• Prandoni, P., Lensing, A. W. A., Büller, H. R., et al. (1992). Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet, 339, 441–5.
   PubMed Web of Science ®Google Scholar
• Simmoneau, G., Charbonnier, B., Decousus, H., et al. (1993). Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proxmal deep vein thrombosis. Arch Intern Med, 153, 1541–6.
   PubMedGoogle Scholar
• Levine, M., Gent, M., Hirsch, J., et al. (1996). A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Eng J Med, 334, 677–81.
   PubMed Web of Science ®Google Scholar
• Koopmann, M. M. W., Prandoni, P., Piovella, F., et al. (1996). Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital compared with subcutaneous low-molecular-weight heparin administered at home. N Eng J Med, 334, 682–7.
   PubMed Web of Science ®Google Scholar
• Cate, J. W., Büller, H. R., Gent, M., et al. (1996). On behalf of the Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Eng J Med, 337, 657–62.
   Web of Science ®Google Scholar
• O'Shaughnessy, D. F., et al. (1998). The Outpatient Management of Deep Vein Thrombosis. J. Accid Emerg Med, 15, 292–293.
   PubMedGoogle Scholar
• Simmoneau, G., Sors, H. and Charbonnier, B. (1997). Low-molecular-weight heparin vs unfractionated heparin in the treatment of acute Pulmonary Embolism. N. Eng J Med, 337(10), 663–669.
   PubMed Web of Science ®Google Scholar
• Buller, H. R., Gent, M. and Gallus, A. S. (1997). for The Columbus Investigators. Low-molecular-weight-heparin in the treatment of patients with venous thromboembolism. N Engl J Med, 337, 657–662.
   PubMed Web of Science ®Google Scholar
• Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Services, Northern Ireland. Report on Confidential Enquiries into Maternal Deaths in UK 91–91 London: Her Majesty's Stationary Office, 1996.
   Google Scholar
• Gillis, S., Shushan, A. and Eldor, A. (1992). Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Brit Jour Obst and Gynae, 39, 297–301.
   Google Scholar
• Forestier, F., Sole, Y., Aiach, M., et al. (1992). Absence of transplacental passage of Fragmin during the second and third trimesters of pregnancy. Thromb Haemost, 67, 180–181.
   PubMed Web of Science ®Google Scholar
• Nelson-Piercy, C., Letsky, E. A. and de Swiet, M. (1997). Am J Obstet Gynecol, 176(5), 1062–1068.
   PubMed Web of Science ®Google Scholar
• Dahlmann, T. C. (1993). Osteoporotic fractures and the recurrence of TE during pregnancy and the puerperium in 184 women undergoing TE with heparin. Am J Obstet Gynecol, 168, 1265–70.
   PubMed Web of Science ®Google Scholar
• Hunt, B. J., Doughty, H.-A., Majumdar, G., et al. (1997). TE with LMWH (Fragmin) in high risk pregnancies. Thromb haemost, 77, 39–43.
   PubMed Web of Science ®Google Scholar
• Dulitzki, M., Pauzner, R., Langevitz, P., et al. (1996). LMWH during pregnancy and delivery—experience with 41 pregnancies. Obstet. Gynecol, 87, 380–3.
   PubMed Web of Science ®Google Scholar
• Wildsmith, J. A. W. and McClure, J. M. (1991). Antico-agulant drugs and central nervous system blockade. Anaesthesia, 46, 613–614.
   PubMed Web of Science ®Google Scholar
• Massicotte, P., Adams, M., Marzinotto, V., Brooker, L. A. and Andrew, M. (1996). Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study. The journal of Paediatrics, 128, 313–318.
   PubMed Web of Science ®Google Scholar
• Andrew, M. (1996). Indications and drugs for antico-agulation therapy in children. Thrombosis Research, 81, S61–73.
   PubMed Web of Science ®Google Scholar